

Investor Overview

December 2023

ProSomnus, Inc. (Nasdaq: OSA)



ProSomnus.com

844.537.5337

DISCLAIMER

This presentation is for informational purposes only and should not be relied on for any other purpose. All information provided is as of the date of this presentation unless otherwise noted and ProSomnus assumes no obligation to update the information in this presentation except as required by law.

Certain industry and market data used in this presentation have been obtained from third-party industry sources as well as from research reports prepared for other purposes. ProSomnus has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy and completeness. All of the market data in the presentation involves a number of assumptions and limitations, and there can be no guarantee as to the reasonableness or reliability of such assumptions. ProSomnus assumes no obligation to update the information in this presentation.

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Statements that are not historical facts, including statements regarding ProSomnus's expected financial and stock performance, ProSomnus's labeling expansion, the timing and impact of its ongoing clinical studies, its future growth and expenses, the plans and capabilities regarding a remote monitoring program, and the growing markets for its devices, are forward-looking statements. Forward-looking statements also include discussions of strategy, financial projections, guidance and estimates (including their underlying assumptions), statements regarding plans, objectives, expectations, or consequences of various transactions or, and statements about our future performance, operations, products, and services, and should be viewed with caution. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are neither statements of historical or current fact nor are they guarantees of future performance. Further, these forward-looking statements are subject to various known or unknown risks, uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors) and changes in circumstances, many of which are beyond our control, difficult to predict as to timing, extent, likelihood, and degree of occurrence, and could cause the actual results to vary materially from those indicated or anticipated.

Such risks and uncertainties include, but are not limited to: (i) uncertainty of the projected financial information with respect to ProSomnus; (ii) ProSomnus's limited operating history and history of losses; (iii) ProSomnus's ability to maintain and grow its profit margin from sales of ProSomnus oral devices; (iv) ProSomnus's ability to expand internationally; (v) the roll-out of ProSomnus's business and the timing of expected business milestones; (vi) ProSomnus's ability to formulate, implement and modify effective sales, marketing, and strategic initiatives to drive revenue growth; (vii) expectations concerning the effectiveness of OSA treatment using ProSomnus oral devices and the potential for patient relapse after completion of treatment; (viii) the understanding and adoption by dentists and other healthcare professionals of ProSomnus oral devices for mild-to-moderate OSA; (ix) risk related to compliance debt covenants or successfully renegotiating such covenants; (x) ProSomnus's ability to obtain additional funding and the risk of potential future significant dilution to stockholders resulting from any such financing or from lender conversions under the convertible debt financing; (xi) the viability of ProSomnus's intellectual property and intellectual property created in the future; (xii) government regulations and ProSomnus's ability to obtain applicable regulatory approvals and comply with government regulations, including under healthcare laws and the rules and regulations of the U.S. Food and Drug Administration; (xiii) the risk of downturns in the market and ProSomnus's industry including, but not limited to, as a result of the COVID-19 pandemic; and (xiv) the outcome of any legal proceedings that may be instituted against ProSomnus.

A further list and description of risks and uncertainties can be found in ProSomnus's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") and any subsequently filed quarterly reports on Form 10-Q, and other documents that ProSomnus may file or furnish with the SEC, which you are encouraged to read and are available on the SEC's website at <http://www.sec.gov>. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Forward-looking statements do not represent our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.


Trademarks

ProSomnus may own or have rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this presentation is not intended to, and does not, imply a relationship with ProSomnus, or an endorsement or sponsorship by or of ProSomnus. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this presentation may appear without the TM, SM, ® or © symbols, but such references are not intended to indicate, in any way, that ProSomnus will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.

ProSomnus Overview



ProSomnus EVO
Precision Medical Device



ProSomnus: The Leading Non- CPAP OSA Treatment


Vision: the leading OSA treatment

- Excellent commercial growth
 - Seven (7) quarters of sequential growth
 - Q3-23 Revenue of **\$7.1M up 41% y/y**
 - YTD Q3-23 Revenue of **\$19.8M up 46% y/y**
 - Prior Year FY2022 Revenue of **\$19.4M up 38% Y/Y**
- ProSomnus devices have scientifically demonstrated 90%+ efficacy
- Next-generation sensor device featuring real time remote monitoring of hypoxic burden is approaching commercialization (2024)
- Head-to-head study vs CPAP, preliminary data presented in Aug 2023
- Pursuing label expansion for Severe OSA (2024)
- \$10M financing closed in September 2023
- Global HQ and Manufacturing in Pleasanton, CA
- Highly experienced management team




Sleep Apnea (OSA) is a Major Public Health Epidemic – CDC


OSA is Recurrent Airway Obstruction, Depriving Vital Organs of Oxygen



1 Billion People Worldwide and 75 Million in the US Have OSA, >80% Undiagnosed (Lancet)




Comorbidities of OSA



Significant Public Health Consequences for Un-/Under- treated OSA

OSA is a key predictor of early mortality

OSA All-Cause Mortality (Wisconsin Sleep Cohort) ⁽¹⁾



Quality of Life Consequences⁽²⁾

- Sleep Divorce
- Professional Performance
 - Workplace productivity (\$86.9B)
 - Accidents (\$6.5B)
 - Absenteeism
- Driving / Motor Vehicle (\$26.2B)
- Combat Readiness (US Armed Forces)
- Academic Performance
- Untreated Cost per Patient 3x vs Treated

Immediate Opportunity

CPAP: Incumbent Therapy



Issue: >50% Terminate CPAP Usage⁽¹⁾

Actionable non-CPAP therapy market opportunity of \$2.2 billion in U.S.

1 Billion People Worldwide Have Undiagnosed OSA (Lancet 2019)

Diagnosed 20%

Mild & Moderate
66%

54 Million Adults in the United States (Lancet 2019)

Diagnosed 20%
10.8 mil (2)

Mild and Moderate
66%

CPAP Failure ~50%

3.6 Million Adults Immediate Addressable Market in US


3.6 Million in US diagnosed with mild to moderate, prescribed a CPAP and have failed/refused CPAP

\$2.2 Billion immediate Addressable Market Opportunity at our ASP of \$600/device

(1) Pépin JL, Bailly S, Rinder P, Adler D, Szeftel D, Malhotra A, Cistulli PA, Benjafield A, Lavergne F, Josseran A, Tamisier R, Hornus P, On Behalf Of The medXcloud Group. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J Clin Med. 2021 Mar 1;10(5):936. doi: 10.3390/jcm10050936. PMID: 33804319; PMCID: PMC7957656 (2)Peppard, PE, Tyong, M Palta, EW Hagen, abd KM Hla. "Increased Prevalence of Sleep-disordered Breathing in Adults" American Journal of Epidemiology (2013): National Center for Biotechnology Information. U.S. National Library of Medicine

ProSomnus EVO Personalized Medical Devices

Proprietary Device Design and Personalization Drives Improved Patient Outcomes



Mechanism of Action: EVO repositions and stabilizes the jaw to reduce airway collapse



ProSomnus' ability to comfortably and safely reposition, stabilize and titrate each patient's mandible with sub-millimeter precision reduces airway collapse.

ProSomnus Devices are ~47% Better at Performing the Mechanism of Action for Oral Appliance Therapy

Mechanisms of Action (to Reduce Airway Collapsibility)***	Traditional OAT Devices*	ProSomnus Precision OAT Devices*	Difference*
a) Reposition the Mandible	+/- 3.7mm	+/- .2mm	+/- 3.3mm
b) Stabilize the Mandible	+/- 1.8mm	+/- .1mm	+/- 1.9mm
c) Titrate the Mandible	+/- 0.5mm	+/- .1mm	+/- 0.4mm
Total	+/- 6.0mm	+/- .4mm	+/- 5.6mm
Implied Efficacy Variance**	50%	3%	47%
* Based on Hu et al, AADSM, 2021			
** 1mm variance equals 8.4% efficacy. Based on Kato 2000, Esaki 1997, Gindre 2008, Aarab 2010 and Walker 2003.			
*** Based on AADSM Definition of an Efficacious Oral Appliance, CMS Coding, FDA Guidance, AASM Guidelines			

ProSomnus precision technologies enable better and more consistent efficacy

ProSomnus Devices Reposition, Stabilize & Titrate the Jaw to Open the Airway

OSA Patient, no Device
Baseline Airway Characteristics

Total Volume:
135cc

Min Area:
122.9mm²

OAT Mechanisms
of action:
1. Reposition
2. Stabilize
3. Titrate
The Jaw into a
position that opens
the airway

OSA Patient, w/ ProSomnus
Airway Characteristics

Total Volume:
202cc

Min Area:
269.9mm²

Total Airway Volume

No device = 135cc's
With ProSomnus 202 cc's
Improvement +50%

Minimum Cross Section

No device = 129mm²
W/ ProSomnus 269.9 mm²
Improvement +120%


ProSomnus Devices Demonstrate Excellent Efficacy

Clinical results including 17 published & 3 presented studies with >1,500 total patients differentiate ProSomnus from incumbent treatments

Study Design and Key Results

- 33 patients suffering from mild / moderate OSA
- Success goal: Oxygen Desaturation Index (ODI) < 10 events per hour
- ProSomnus success rate 94% vs ~50% for CPAP
- 97% reported significant reduction in snoring
- Excellent safety profile

94% Successfully Treated with ProSomnus




18 mild, 15 moderate patient types.

Source: Senders et. al., 2003, The surgical treatment of obstructive sleep apnea; Mosca EV, Bruehlmann S, Zouboules SM, et al. In-home mandibular repositioning during sleep using MATRx plus predicts outcome and efficacious positioning for oral appliance treatment of obstructive sleep apnea. J Clin Sleep Med. 2022;18(3):911-919; <https://clinicaltrials.gov/ct2/show/NCT03217383>.

Recent Data

2x More Effective than CPAP⁽¹⁾




(1) Excerpt from 8/11/2023 Presentation by Dr. Olivier Vanderveken

“Comparison of clinical effectiveness and patients’ preference for two non-invasive treatment options for patients diagnosed with moderate to severe obstructive sleep apnea: the FLOSAT study”

93% Success Treating OSA to SAS-HB < 60 (n = 152)⁽²⁾

Figure 1. Individual Responses to Precision Oral Appliance Therapy



(2) Excerpt Mosca et al from CHEST lecture, October 2023

Assessing Precision Oral Appliance Efficacy Using Frequency-Based and Risk-Based Indices

SAS-HB = Sleep Apnea Specific Hypoxic Burden

Growing Portfolio of Peer Reviewed Clinical Data

Clinical results demonstrate ProSomnus's ability to provide improved patient outcomes

Study Name	Sample Size	Classification	Key Finding
Military 3	360	Independent	Improved Quality of Life
Military 1	288	Independent	88.1% success for all severities
San Diego Registry	211	Independent	AHI and ESS Improved
Syracuse	115	Independent	91% success for mild/moderate
NOTUS3	58	Independent	94% success for mild/moderate
Multi-Center	55	Company Supported	98% success for mild/moderate
Detroit Registry	50	Independent	92% success for mild/moderate
NOTUS2	48	Independent	90% success for mild/moderate
Multicenter preference	31	Company Supported	100% preferred
EFFECTS Study	28	Company Supported	93.6% compliance
Alaska 3	26	Independent	62% improvement
Military 2	24	Independent	87.5% success for all severities
Carlton Study	20	Independent	75% improvement
UoP	18	Independent	No change in teeth/bite
India	10	Independent	No change in teeth/bite
Alaska 2	8	Company Supported	87.9% compliance
Alaska 1	7	Company Supported	71% improvement
Syracuse	91	Company Supported	89% success all severities (AHI<10)
Total Patients	1,448		

See Appendix for complete clinical study citations.

- 17 Clinical Studies featured in peer reviewed publications demonstrating strong:
 - Efficacy
 - >90% (mild/moderate)
 - >87% (all severities)
 - >97% (snoring)
 - Patient Compliance
 - ~90%
 - Safety
 - ProSomnus precision intraoral devices did not demonstrate the types of unwanted tooth movements and bite changes that have been reported in the literature with CPAP and legacy dental products
 - Patient Preference
 - 100%
- 3 Conference podium presentations and abstracts
- >1,500 Patients in published & presented studies

Excellent Reimbursement Coverage in the U.S. and Key European Markets

Strong reimbursement coverage in the U.S. and Europe provides ProSomnus with attractive economics

- **Covered by Medicare and nearly all private U.S. medical insurance**

- CPT codes E0486 & K1027
- >200 million covered lives




- **Robust international coverage**

- Germany, GKV
- UK, NHS
- France, Social Insurance
- Netherlands, Zorginstituut
- ... and more ...



Patient Journey



Multiple Meaningful Growth Catalysts


Significant value-creating catalysts



**North America Sales
Referral Initiative**
(Initiated 2023)



**Launch of Our Remote Patient
Monitoring Device for OSA**
(2024)



Severe OSA Label Expansion
(2024)



**International
Sales Expansion**
(Initiated 2023)

Reimbursed OSA Remote Monitoring Platform – Potential Game Changer

Unique ability to monitor efficacy, compliance and health has potential to make ProSomnus front line therapy vs alternate therapy

Sensor Device



Parameters Monitored

- Continuous oxygen
- Compliance
- Sleep apnea events
- Heart rate
- Heart rate variability
- Pulse rate
- Blood oxygen


Data

Patient App



Data

Healthcare Provider Portal




- Monitoring of physiologic parameters that are highly predictive of health risks
- Sleep Apnea Specific Hypoxic Burden
- Sleep Apnea Specific Pulse Rate Variability

- Expected commercial introduction 2024

Existing remote patient monitoring reimbursement codes have the potential to create compelling economics and scalable disease management

Strong Record of Top-Line Growth

Trailing 12-Month Revenue



- Seven (7) quarters of sequential growth
- Q3-23 Revenue **\$7.1M up 41% y/y**
- YTD Q3-23 Revenue **\$19.8M up 46% y/y**
- FY2022 Revenue **\$19.4M up 38% Y/Y**
- Post Market Surveillance
 - 99% Customer Retention
 - 99% Would Recommend ProSomnus
 - 98% Overall and Patient Satisfaction
- Over 200 million lives eligible to receive ProSomnus OAT covered by medical insurance
 - Commercial payers
 - Government insurance: US Medicare, Germany, Netherlands, UK, etc.

	Three-month period ended			Sequential Q/Q		Sequential Q/Q		Year-to-Date September 30		\$ Inc	% Inc
	September 30, 2023	June 30, 2023	September 30, 2022								
Revenue	\$ 7,071,445	\$ 6,933,910	\$ 4,997,979	\$ 137,535	2.0%	2,073,466	41.5%	\$ 19,813,735	\$ 13,601,031	\$ 6,212,704	45.7%

AI-Enhanced Manufacturing Enables Differentiation & Scalability

Proprietary Precision Manufacturing Platform Creates Scalable Barrier to Entry

Digital Prescription



A.I. Device Design



Advanced Materials




Robotic Milling




Custom Precision Medical Devices



Digital Device Design Time (mins)



Digital Robotic Milling Time (mins)



Experienced Management Team

Experienced industry executives with a strong track record of commercializing novel products

Len Liptak, MBA
Chief Executive Officer



Brian Dow
Chief Financial Officer



Sung Kim
Chief Technology Officer



John Remmers, MD
Chief Scientist



Edward Stall, MD, DDS, MBA
Medical Director





PROSOMNUS®
SLEEP TECHNOLOGIES

Contacts

Website: <https://investors.prosomnus.com/>

Email: investors@prosomnus.com

Company Contact: bdow@prosomnus.com

Investor Relations: mike.cavanaugh@westwicke.com

Appendix: Clinical Study Citations

Study Name	Sample Size	Classification	Key Finding	Reference
Military 3	360	Independent	Improved Quality of Life	US Army Public Health Center Report: Obstructive Sleep Apnea Surveillance and Oral Appliance Therapy Evaluation, Active Duty U.S. Army, 2014–2019, May 2022
Military 1	288	Independent	88.1% success for all severities	Knowles S, Dekow M, Williamson ML. Oral Appliances for OSA Treatment: Meeting the Quadruple Aim. Mil Med. 2021 Aug 19;usab316. doi: 10.1093/milmed/usab316. Epub ahead of print. PMID: 34411239.
San Diego Registry	211	Independent	AHI and ESS Improved	Rohatgi R. Is the Relationship Between OAT Outcomes, Dosage and OAT Device Type as Expected? A Private Practice, Retrospective Cohort Study. Journal of Dental Sleep Medicine. Vol. 6, No.3 2019. Abstract #030.
Syracuse	115	Independent	91% success for mild/moderate	Sall E. Precision Oral Appliance Therapy: The Prime-Time Treatment for OSA. World Sleep Congress. Rome, Italy. Poster Abstract #289. March 2022.
NOTUS3	58	Independent	94% success for mild/moderate	Mosca EV, Bruehlmann S, Zouboules SM, et al. In-home mandibular repositioning during sleep using MATRx plus predicts outcome and efficacious positioning for oral appliance treatment of obstructive sleep apnea. J Clin Sleep Med. 2022;18(3):911–919.
Multi-Center	55	Company Supported	98% success for mild/moderate	Smith K; Carollo J; Desai A; Murphy M. Efficacy of a Novel Precision Iterative Device and Material. World Sleep Congress. Rome, Italy. Poster Abstract #081. March 2022.
Detroit Registry	50	Independent	92% success for mild/moderate	Murphy M, Munro K. Device Design's Impact on Dose in Oral Appliance Therapy. Journal of Dental Sleep Medicine. Vol. 8, No. 3 2021. Abstract #004.
NOTUS2	48	Independent	90% success for mild/moderate	Remmers JE, Topor Z, Grosse J, Vranjes N, Mosca EV, Brant R, Bruehlmann S, Charkhandeh S, Zareian Jahromi SA. A Feedback-Controlled Mandibular Positioner Identifies Individuals With Sleep Apnea Who Will Respond to Oral Appliance Therapy. J Clin Sleep Med. 2017 Jul 15;13(7):871-880. doi: 10.5664/jcsm.6656. PMID: 28502280; PMCID: PMC5482578.
Multicenter preference	31	Company Supported	100% preferred	Elliott E, Ehtessabian J, Murphy M, Rein J, Seltzer N, Schwartz D, Shah S, Smith K. A Multi-Center Preference study of a Novel Oral Appliance Design and Material for Better Provider, Physician, Patient and Payer Acceptance. SLEEP Journal. Vol. 44, Abstract Supplement, 2021. Abstract #440. Page A 174.
EFFECTS Study	28	Company Supported	93.6% compliance	Stern J, Lee K, Kuhns D, et al. (June 02, 2021) Efficacy and Effectiveness of the ProSomnus® [IA] Sleep Device for the Treatment of Obstructive Sleep Apnea: EFFECTS Study. Cureus 13(6): e15391. DOI 10.7759/cureus.15391
Alaska 3	26	Independent	62% improvement	Hu JC, Comisi JC. Vertical dimension in dental sleep medicine oral appliance therapy. Gen Dent. 2020 Jul-Aug;68(4):69-76. PMID: 32597782.
Military 2	24	Independent	87.5% success for all severities	Kang CRS, Knowles S, Dekow M. The Success of Oral Appliance Therapy Based on Symptom-Driven Titration. Mil Med. 2022 Aug 20;usac248. doi: 10.1093/milmed/usac248. Epub ahead of print. PMID: 35986605.
Carlton Study	20	Independent	75% improvement	Carlton D, Is Selecting the Appropriate Sleep Device Important for You and Your Patient Important? Dental Sleep Practice, Summer 2016.
UoP	18	Independent	No change in teeth/bite	Vranjes N, Santucci G, Schulze K, Kuhns D, Khai A. Assessment of potential tooth movement and bite changes with a hard-acrylic sleep appliance: A 2-year clinical study. J Dent Sleep Med. 2019;6(2)
India	10	Independent	No change in teeth/bite	Aziz R, Somaiah S, Kalha AS, Reddy G, Muddaiah S, Shetty B. Comparative assessment of changes in pharyngeal airway space in cases of obstructive sleep apnoea with a customized mandibular repositioning appliance - a clinical study. Sleep Sci. 2021 Jan-Mar;14(Spec1):16-24. doi: 10.5935/1984-0063.20200072. PMID: 34917269; PMCID: PMC8663729.
Alaska 2	8	Company Supported	87.9% compliance	Hu J, Liptak L. Evaluation of a new oral appliance with objective compliance recording capability: a feasibility study. Journal of Dental Sleep Medicine. 2018;5(2):47–50.
Alaska 1	7	Company Supported	71% improvement	Hu et al, Dental Sleep Practice, March 2015.
Syracuse	91	Company Supported	89% success all severities (AHI<10)	Sall E, Smith K, Desai A, et al. (December 07, 2023) Evaluating the Clinical Performance of a Novel, Precision Oral Appliance Therapy Medical Device Made Wholly From a Medical Grade Class VI Material for the Treatment of Obstructive Sleep Apnea. Cureus 15(12): e50107. doi:10.7759/cureus.50107
Total Patients	1,448			